Meg E. Fasulo

Current Representations

Viasat, Inc. v. Western Digital Corporation, et al.; Viasat, Inc. v. Kioxia Corporation, et al. (W.D. Tex.)
Trial counsel for Viasat in patent infringement actions regarding forward error correction technology in NAND flash memory. Forward error correction can significantly improve the reliability and lifespan of NAND flash memory products, which are notoriously error prone. Cases are currently pending.

Northwestern University v. Universal Robots, et al. (D.Del. and N.D. Ill.)
Trial counsel for Northwestern University in a series of patent infringement cases against the manufacturers of certain industrial robots that were invented at Northwestern University in the research laboratories of Drs. Michael A. Peshkin and J. Edward Colgate. The asserted patents—U.S. Patent Nos. 6,928,336, 6,907,317, and 7,120,508—claim groundbreaking work on intelligent assist systems known as collaborative robots or “cobots,” programmable robotic devices that can safely interact with human operators in a shared workspace. The lawsuits are part of Northwestern’s overall stewardship of life-changing technology developed by its faculty through the enforcement of intellectual property rights, as well as technology licensing, corporate partnerships, entrepreneurial support, and startup creation. Read the Complaint here, and coverage in the press here, here, and here.

Regents of the University of Minnesota v. Gilead Sciences, Inc., (N.D. Cal.)
Counsel for Gilead in patent infringement litigation related to Gilead’s hepatitis C treatments. District court litigation is currently pending. The Patent Trial and Appeal Board instituted an inter partes review and ruled that U.S. Patent No. 8,815,830 was anticipated by Gilead’s disclosure of the compound sofosbuvir. Case is now on appeal.

Regents of the University of Minnesota v. Gilead Sciences, Inc. (N.D. Cal.)
Trial counsel for Gilead in patent infringement action related to Gilead's hepatitis C treatments. Case pending.

Other Representative Cases

Colibri Heart Valve, LLC v. Medtronic CoreValve LLC (C.D. Cal.)
Trial counsel in a patent infringement case against the manufacturer of transcatheter aortic valve replacement (TAVR) devices. The trial team obtained a $106.5 million verdict for their client, Colibri Heart Valve. After a one-week trial and five hours of deliberation, the jury returned a verdict finding that the defendant Medtronic CoreValve induced infringement of Colibri Heart Valve’s patented and life-saving method of replacing a patient’s native valve percutaneously and failed to prove that the patent claims were invalid. John Hughes, Steve Derringer, Matthew Ford, and Katherine Rhoades rounded out the Bartlit Beck trial team. The victory was recognized by Law360 available here.

Align Technology, Inc. v. 3Shape A/S (W.D. Tex.)
Counsel for Align Technology (maker of the popular Invisalign system) in patent litigation related to intraoral scanner technology.

ViiV Healthcare v. Gilead Sciences, Inc. (D. Del.)
Counsel for Gilead in patent infringement case related to Gilead's Biktarvy HIV treatment. 

Adverio Pharma GmbH et al. v. Alembic Pharmaceuticals, Ltd. et al. (D. Del.)
Trial counsel for plaintiffs in Hatch-Waxman litigation relating to Bayer's Adempas® (riociguat) product. The case settled favorably at the end of a bench trial before Judge Leonard P. Stark.

Regents of the Univ. of Minn. v. LSI Corp., et al. (Fed. Cir.)
Counsel for permissive intervenor Gilead Sciences in case of first impression regarding application of state sovereign immunity to inter partes review proceedings before the United States Patent and Trademark Office. In a precedential opinion on June 14, 2019, the Federal Circuit held that States were not immune from such proceedings. The Supreme Court later denied the University's petition for writ of certiorari in what was identified by Law360 as one of the "Biggest Patent Rulings Of 2019." Read about the case here

UroPep v. Eli Lilly (Fed. Cir.)
Appellate counsel for UroPep, securing a plaintiff verdict in a patent infringement jury trial concerning Eli Lilly's sales of Cialis to treat benign prostatic hyperplasia (BPH).